Advancing Immuno-Oncology: Strategies for ‘Cold’ Tumor Response

Approaches focused on recruiting and activating tumor-infiltrating T cells are demonstrating potential to reshape the immunosuppressive tumor microenvironment, thereby enhancing the efficacy of immunotherapy in patients with microsatellite stable (MSS) and low microsatellite instability (MSI-low) colorectal cancers. These cancers, often referred to as “cold” tumors due to their limited immune response, present a significant challenge in cancer treatment.

Traditional immunotherapy, while effective in a subset of patients, frequently enough fails in MSS/MSI-low colorectal cancers as of this lack of pre-existing immune infiltration. Current research explores methods to convert these “cold” tumors into those susceptible to immune attack. Strategies include utilizing agents that modulate the tumor microenvironment, making it more conducive to T cell activity, and combining these with checkpoint inhibitors to unleash the potential of activated immune cells.

Oncolytic viruses represent a promising alternative approach to stimulate antitumor immunity within these challenging tumors. These engineered viruses selectively infect and lyse cancer cells, releasing tumor-associated antigens and triggering an immune response. This process not only directly kills cancer cells but also alerts the immune system to the presence of the tumor, perhaps leading to a more sustained and effective antitumor response.

Further examination into these and other emerging strategies is crucial to broaden the applicability and improve the outcomes of immunotherapy for a wider range of colorectal cancer patients.